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ABSTRACT
Endothelial cell-specific molecule-1 (ESM-1), also known as endocan, is a soluble proteoglycan expressed 
by the vascular endothelium, which also circulates in the bloodstream. Inflammatory cytokines and proan-
giogenic growth factors increase its expression, and increased serum levels have been reported in several 
cancer types and immunocompetent patients with sepsis. The aim of this study was to analyze the expression 
profile of CXC-chemokines and the effects of ESM-1 gene knockdown in proliferation, migration and CXC-
chemokine expression in highly metastatic human prostate PC-3 cells. Expression profiles of CXC-chemo-
kines were analyzed in metastatic PC-3 and non-tumorigenic PWR-1E cells. siRNA-mediated knockdown of 
ESM-1 was performed into PC-3 cells, which were subsequently tested for cell migration and proliferation. 
Effect of siRNA transfection on CXC-chemokine expression was further quantified at the transcript and pro-
tein level. RT-qPCR analysis and sandwich ELISA assay revealed higher levels of ESM-1 and several CXC-
chemokines in metastatic PC-3 cells compared to non-tumorigenic PWR-1E. Transfection of PC-3 cells with 
ESM-1-siRNA decreased cell migration with no effect on proliferation, and it was accompanied by decrease 
in the transcript and protein levels of the angiogenic chemokine CXCL3. We report here for the first time the 
ESM-1 targeting in PC-3 cells, which resulted in decreased migration, which may be related, at least in part, 
to decreased expression of the angiogenic CXCL3 chemokine, whose expression was found to be reduced in 
ESM-1-siRNA transfected cells. Additional studies are required to ascertain the biological role of ESM-1 in 
prostate cancer cells and the link with the expression of CXCL3. (Int J Biomed Sci 2017; 13 (1): 35-42)
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INTRODUCTION
Endothelial cell-specific molecule-1 (ESM-1), also 
known as endocan, is a secreted proteoglycan whose tran-
scripts were initially detected from a variety of cultured 
human endothelial cells of different origins, including 
coronary, pulmonary artery, dermal, and capillary endo-
thelial cells (1, 2). More recent studies have reported its 
expression by epithelial tumor cells and cancer cell lines, 
such as prostate cancer cells (3, 4), melanoma cells (5, 6), 
and glioblastoma cell lines(7). It has been found also in the 
blood circulation of healthy subjects (8), and increased lev-
els have been reported in patients with different patholo-
gies, including inflammatory bowel disease (9), hepatocel-
lular carcinoma (10), acute myeloid leukemia (11), among 
others.
ESM-1 is regarded as a marker of angiogenesis, an im-
portant factor in the progression of cancer (12). Its tran-
scriptional expression has been shown to be regulated by 
angiogenic growth factors, such as vascular endothelial 
growth factor (VEGF), and by inflammatory cytokines, 
such as tumor necrosis factor alpha (TNF-α) (13).
Angiogenesis is a process shown to be regulated by 
different factors, produced by both tumor cells and host 
responding cells (14). Among the regulatory factors, in-
creasing evidence supports the important role of CXC 
chemokines in the process of angiogenesis (15, 16). The 
majority of CXC chemokines contain at the NH2 terminus 
a three-amino-acid motif (Glu-Leu-Arg: the ELR motif), 
which precedes the first cysteine amino acid of the prima-
ry structure of these cytokines (17). The CXC chemokine 
family members that contain the ELR motif (ELR+) are 
potent promoters of angiogenesis (18), while members that 
lack the ELR motif (ELR−) are potent inhibitors of angio-
genesis, or angiostatic (18, 19). 
We have previously reported the over-expression of 
ESM-1 in prostate cancer cell lines from rat (3) and hu-
man origin (4). The aim of this work was to analyze the 
expression profile of CXC-chemokines and the effects of 
ESM-1 gene knockdown in proliferation, migration and 
CXC-chemokine expression in highly metastatic human 
prostate PC-3 cells. 
MATERIALS AND METHODS
Cultured cell lines 
Human bone metastasis-derived prostate cancer PC-3 
cells (ATCC® CRL-1435) and non-tumorigenic human 
prostatic epithelial PWR-1E cells (CRL-11611) were ob-
tained from the ATCC (Manassas, VA). PC-3 cells were 
routinely maintained in phenol red-positive F-12K modi-
fied medium (ATCC) containing 10% FBS and 1% pen-
icillin-streptomycin. PWR-1E cells were maintained in 
keratinocyte serum-free medium (Life Technologies) 
supplemented with 50 μg/mL bovine pituitary extract, 5% 
L-glutamine, and 5 ng/mL epidermal growth factor. Cells 
were grown as monolayers in T-25 tissue culture flasks, 
in a humidified atmosphere containing 5% CO2 at 37°C 
and passaged once/twice a week. For all the experiments, 
cells were harvested at low passage numbers: PC-3 cells 
between passages 28 and 31, and PWR-1E between pas-
sages 18 and 22. 
siRNA-mediated knockdown of ESM-1 gene expression
Small interfering RNA targeting the ESM-1 gene 
(siESM-1) and scramble siRNA sequence (siControl), 
were purchased from Qiagen (FlexiTube GeneSolution 
GS11082 for ESM-1). PC-3 cells were seeded into 12-well 
cell culture plates (Corning®) and incubated for 24 h in 
Opti-MEM® reduced serum medium (GIBCO) without 
FBS. Then, cells were subjected to transfection with ei-
ther siESM-1 or siControl using the RNAi Human/Mouse 
Starter Kit (Qiagen) following the manufacturer’s instruc-
tions. Briefly, 300,000 cells were mixed with siRNAs so-
lution complexed with the transfection reagent, and the 
mixture was incubated at normal culture conditions for 48 
hours. Non-transfected (NT) cells treated in the same way 
were used as control.
Cell viability and proliferation assays
To measure the cell survival and proliferation rate of 
PC-3 cells, after treatment with siESM-1 or siControl, cell 
viability and proliferation were analyzed 48 h post-trans-
fection using two methods: a direct cell counting using try-
pan blue dye exclusion and a colorimetric MTS-based cell 
viability kit (CellTiter 96 Aqueous One Solution Cell Pro-
liferation Assay, Promega®). For trypan blue dye exclusion 
method, PC-3 cells transfected with siRNAs were mixed 
with 10 ul trypan blue (0.4% in PBS) and the number of 
viable, unstained cells, was determined using a Neubauer 
chamber. For the MTS-based assay, PC-3 cells transfected 
with siRNAs were mixed with 20 μL CellTiter solution 
(Promega) and incubated for an additional 4 h at 37°C. 
Then, absorbance was measured at 490 nm in a Multiskan 
FC microplate reader (Thermo Scientific). MTS [3-(4,5-di-
methylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt] is a tetrazolium 
salt that is reduced to water-soluble formazan mainly by 
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mitochondrial dehydrogenase enzymes found in metaboli-
cally active cells. The quantity of formazan product as 
measured by the amount of 490nm absorbance is directly 
proportional to the number of living cells in culture (20).
Scratch assay for analysis of cell migration in vitro
To evaluate the effect of ESM-1 gene expression knock-
down in cell migration, the scratch assay was performed 
(21). PC-3 cells were seeded onto 6-well plates at density 
of 3 × 106 cells/well, and incubated at 5% CO2 and 37oC for 
24 h. Then, cells were transfected with ESM-1-siRNA or 
control-siRNA, and incubated for additional 24h. Media 
was subsequently replaced by serum-free Opti-MEM and 
cells were incubated until they reached 90-100% conflu-
ence. At this point, a vertical scratch was performed on 
PC-3 cells monolayer using a sterile 1,000 μl micropipette 
tip. Cells were carefully washed with Opti-MEM to re-
move scratched cells, and further incubated at 37°C in fresh 
Opti-MEM. Wound closure was monitored every 12 h post 
scratch with a trinocular inverted microscope (Motic AE31). 
Images were analyzed with the TScratch software (22). Ex-
periments were performed in triplicates. Untransfected and 
control-siRNA transfected cells were used as controls.
Total RNA extraction and quality control
Untransfected PWR-1E cells were used as the refer-
ence cell line for comparison of gene expression between 
transfected and untransfected conditions. To analyze the 
effects of siRNA transfection in gene expression, control-
siRNA transfected PC-3 cells were used as control. To-
tal RNA was isolated from PC-3 cells on the following 
conditions: untransfected, ESM-1-siRNA transfected, and 
control-siRNA transfected. RNA isolation was performed 
with TRI-Reagent (Ambion), following the manufac-
turer’s instructions. The concentration and purity of the 
extracted total RNA was assessed spectrophotometrically 
by measuring OD260 and OD260/280 ratio respectively in 
RNase-free H2O using Nanodrop 2000c (Thermo Scientif-
ic). Three replicates of each RNA sample were measured 
and the measured concentrations were averaged. For all 
samples OD260/280 ratio was ~2.0. Total RNA samples 
were stored at −80°C until used.
cDNA synthesis and reverse transcription quantitative 
real-time PCR (RT-qPCR)
RNA samples from cell lines were processed for reverse 
transcription using the QuantiTect Reverse Transcriptase 
kit (Qiagen). First, to eliminate any contaminating genomic 
DNA, 1μg of total RNA was incubated with genomic DNA 
Wipeout Buffer (Qiagen) for 2min at 42°C. The reverse-
transcription master mix, containing QuantiTect RT en-
zyme, QuantiTect RT Buffer and RT Primer Mix (oligo-dT 
and random primers), was prepared and added to the tem-
plate RNA. Samples were incubated at 42°C for 15 min, 
followed by inactivation at 95°C for 3 min. A 20 μL final 
volume of cDNA was stored at −20°C until used in qPCR. 
Transcript expression levels for ESM-1, ELR+ CXC 
chemokines (CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, 
CXCL7, and CXCL8), ELR− CXC chemokines (CXCL4, 
CXCL9, CXCL10, CXCL11, CXCL12, and CXCL14), and 
reference genes HPRT-1 and β-actin were analyzed in the 
cell lines by qPCR using QuantiTect SYBR Green PCR 
Master Mix (Qiagen). Primers specific for ESM-1 and the 
reference genes HPRT-1 and β-actin were designed with 
Primer-BLAST (23) using sequences from GenBank data-
base. All primers were designed to span at least one exon–
intron boundary to avoid detection of residual genomic 
DNA. For gene expression analysis of CXC-chemokines, 
Chemokines qSTAR qPCR primer panels (HPP6004A) 
were purchased from OriGene Technologies (Rockville, 
MD). qPCR reactions for each sample were carried out in 
triplicates, using QuantiTect® SYBR® Green PCR Master 
Mix (Qiagen) in a StepOne thermocycler (Applied Biosys-
tems), with an initial denaturing step at 95ºC for 15 min, 
followed by 40 cycles of amplification of 95 °C for 15 s, 
55 °C for 45 s and 60°C for 1 s. Negative controls (non-
template control and negative reverse transcriptase control) 
were also included. Relative changes in gene expression 
for each target gene in the cell lines were calculated with 
the Sequence Detection System 2.1 software (Applied 
Biosystems), using the comparative C
T
 method (2–ΔΔCT). 
Expression levels for each target gene were normalized to 
the expression levels of the reference genes HPRT1 and 
β-Actin. Melting curves for all samples were acquired for 
quality control purposes.
Enzyme-linked immunosorbent assay for CXC Che-
mokine measure
Supernatants were collected from cells cultured in 
serum free medium for 48 hours. Cell supernatants were 
cleared by centrifugation at 13,000 rpm for 5 min. Protein 
level for each chemokine was measured by quantitative 
enzyme-linked immunosorbent assay (ELISA). CXCL1/
GROα, CXCL8/IL8, CXCL9/MIG, CXCL10/ IP-10, and 
CXCL11/I-TAC protein levels were determined using the 
Human Common Chemokines Multi-Analyte ELISArray 
Kit (SABiosciences, Qiagen, Valencia, CA, USA), while 
CXCL3 protein level was determined with a single ELISA 
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assay kit (Cat #: MBS910472, Mybiosource, San Diego, 
CA, USA). Briefly, 50 µL of medium was incubated in a 
96-well plate for 1 hour at RT, followed by washing steps, 
incubation with detection antibodies for 1 hour, wash-
ing, incubation with avidin-horseradish peroxidase for 30 
minutes, washing, development for 15 to 30 minutes, and 
termination of the development with stop solution. Che-
mokine protein levels were measured on a MultiSkan mi-
croplate reader (Thermo) with an absorbance at 450 nm. 
Sampling was performed in triplicates.
Enzyme-linked immunosorbent assay for ESM-1 measure
Supernatants were collected from cells cultured in 
serum free medium for 48 hours. Cell supernatants were 
cleared by centrifugation at 13,000 rpm for 5 min. ESM-1 
protein levels were measured using a commercial enzyme-
linked immunosorbent assay (Aviscera Biosciencies, Santa 
Clara, CA, USA) according to the manufacturer’s instruc-
tions. A microwell plate was coated with 100 μl of capture 
antibody (1 µg/ml) against ESM-1, incubated overnight at 
4°C, and then coated again with 1% BSA. Then, 100 μl of 
serially diluted ESM-1 standard solution included in the 
ELISA kit, and samples diluted fivefold in dilution buffer 
(2% BSA in PBST) were applied to wells in triplicate and 
incubated with 0.25 μg/ml detection antibody for 1 h, at 
room temperature. After washing the wells with PBST so-
lution, 100 μl of diluted HRP-conjugated streptavidin was 
applied to each well for 30 min. Subsequently, tetrameth-
ylbenzidine (TMB) solution was added to the wells, and 
then the reaction was stopped with 1 N H2SO4 solution. 
The absorbance was then measured at 450 nm on a Multi-
Skan microplate reader (Thermo).
Statistical analysis 
For relative mRNA expression quantification, the 
comparative C
T
 method (2–ΔΔCT) was used, and expression 
levels for each sample were normalized to the expression 
level of the reference genes HPRT1 and β-Actin. qPCR 
experiments were conducted in triplicate. A p<0.05 was 
considered statistically significant. For single ESM-1 and 
CXCL3 ELISA assays and for multi-analyte ELISA array, 
data were reported as mean ± SEM. Statistical difference 
in gene expression for ESM-1 and for each chemokine, 
between PC-3 prostatic cancer cell line and the control 
cell line, and between PC-3 cells transfected with ESM-
1-siRNA and PC-3 cells transfected with control-siRNA, 
was calculated with the T-test using GraphPad Prism 5 
software (GraphPad Software Inc, San Diego, CA); p<0.05 
was considered statistically significant. 
RESULTS
ESM-1 and CXC chemokine expression in PC-3 pros-
tate cancer cells
Transcript and protein expression data for ESM-1 and 
CXC chemokines are presented in Figure 1. Overall, qPCR 
results showed that, compared to non-tumorigenic PWR-
1E cells, metastatic PC-3 cells overexpressed transcripts 
encoding ESM-1 and transcripts encoding the ELR+ CXC 
chemokines CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, 
and CXCL8. Conversely, transcripts encoding the ELR− 
CXC chemokines CXCL9, CXCL10, CXCL11, and 
CXCL14 were not detected in either PC-3 or PWR-1E cells 
(Figure 1A). At the protein level, ESM-1 ELISA assay con-
firmed the high expression level of ESM-1 in the superna-
tant of cultured PC-3 cells. ESM-1 was not detected in the 
supernatant of the control non-tumorigenic PWR-1E cells. 
Multiplex and single ELISA assays confirmed the differ-
ential CXC chemokine profiles between PC-3 cells and the 
control non-tumorigenic PWR-1E cells. Culture medium 
from PC-3 cells had high levels of ELR+ CXC chemokines 
CXCL1, CXCL3, and CXCL8 but low levels of ELR- CXC 
chemokines CXCL9 and CXCL10, and non- detected lev-
els of CXCL11. In contrast, the non-tumorigenic PWR-1E 
cells had low levels of both ELR+ and ELR- CXC chemo-
kines (Figure 1B). These results are consistent with the 
highly metastatic phenotype of PC-3 cells and the non-
tumorigenic phenotype of PWR-1E cells.
ESM-1 and CXC chemokine expression of siRNA 
transfected PC-3 cells 
ESM-1 and CXC-chemokine genes, which are im-
plicated in invasion and migration, were analyzed at the 
transcript and protein levels by qPCR and ELISA, respec-
tively, in PC-3 cells transfected with either ESM-1-siRNA 
or control-siRNA (Figure 2). As shown in Figure 2A, at 
48 h post transfection, the transcript level of ESM-1 in 
cells transfected with ESM-1 siRNA were significantly 
reduced compared with cells transfected with control 
siRNA. Knockdown of ESM-1 in PC-3 cells did not af-
fect the transcript expression of most CXC chemokines, 
except for CXCL3. PC-3 cells transfected with ESM-1 
siRNA had significantly lower transcript levels of CXCL3 
compared to PC-3 cells transfected with control-siRNA. 
Decreased expression of CXCL3 was specific for ESM-1 
siRNA transfected PC-3 cells since there was no signifi-
cant difference in CXCL3 transcript expression in untrans-
fected PC-3 cells compared to PC-3 cells transfected with 
control-siRNA. CXCL7, CXCL9, CXCL10, CXCL11 and 
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Figure 1. ESM-1 and CXC-chemokine expression in PC-3 
cells relative to non-tumorigenic PWR-1E cells. A, Transcript 
expression levels for ESM-1, ELR+ CXC chemokines (CXCL1, 
CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8), and 
ELR− CXC chemokines (CXCL4, CXCL9, CXCL10, CXCL11, 
CXCL12, CXCL14), were analyzed in the cell lines by RT-
qPCR. Relative changes in gene expression for each target gene 
were calculated using the comparative C
T
 method (2–ΔΔCT) nor-
malizing to the expression levels of reference genes (HPRT-1 
and β-actin). Greater than twofold expression changes were 
regarded as significant and are marked by asterisks; B, Protein 
levels were measured using quantitative commercial enzyme-
linked immunosorbent assay/ELISA for ESM-1 and CXC che-
mokines, according to the manufacturer’s instructions. Che-
mokines evaluated were CXCL1/GROα, CXCL3, CXCL8/IL8, 
CXCL9/MIG, CXCL10/ IP-10, and CXCL11/I-TAC. ESM-1 and 
CXC chemokine levels in cell supernatants are shown as mean 
± SEM.
Figure 2. ESM-1 and CXC chemokine expression of siRNA 
transfected PC-3 cells. A, At 48 h post transfection, transcript 
level of ESM-1 in cells transfected with ESM-1 siRNA was sig-
nificantly reduced compared with cells transfected with con-
trol siRNA. Knockdown of ESM-1 in PC-3 cells did not affect 
the transcript expression of most CXC chemokines, except for 
CXCL3. ESM-1 silencing was associated to decreased transcript 
levels of CXCL3 chemokine, compared to cells transfected 
with control siRNA or untransfected cells; B, Knockdown of 
ESM-1 in PC-3 cells significantly reduced the ESM-1 protein 
level and it was associated to decreased level of CXCL3. ESM-1 
knockdown did not affect the protein expression of the remain-
ing CXC chemokines evaluated. Chemokines evaluated were 
CXCL1/GROα, CXCL3, CXCL8/IL8, CXCL9/MIG, CXCL10/ 
IP-10, and CXCL11/I-TAC. ESM-1 and CXC chemokine protein 
levels in cell supernatants are shown as mean ± SEM. siControl: 
PC-3 cells transfected with control siRNA.siESM-1: PC-3 cells 
transfected with ESM-1 siRNA for 48 h.
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CXCL14 were non detected (ND) in PC-3 cells. There was 
no significant difference in the transcript expression of the 
remaining CXC chemokines associated to the knockdown 
of ESM-1 in PC-3 cells. At the protein level, expression of 
ESM-1 and CXCL3 in cells transfected with ESM-1 siR-
NA was significantly reduced compared with cells trans-
fected with control siRNA. Knockdown of ESM-1 in PC-3 
cells did not affect the protein expression of the remaining 
CXC chemokines evaluated: CXCL1/GROa, CXCL8/IL8, 
CXCL9/MIG, CXCL10/ IP-10, and CXCL11/I-TAC (Fig-
ure 2B).
Effect of ESM-1 siRNA knockdown in viability and 
proliferation of PC-3 cells 
Cell viability was evaluated using the direct cell count-
ing trypan blue exclusion (A) and the MTS-based cell ti-
ter viability assay (B). Neither the viability (Figure 3A), 
nor the proliferation (Figure 3B), of PC-3 cells transfected 
with ESM-1 siRNA were significantly different to that of 
PC-3 cells transfected with control siRNA. Forty-eight 
hours after transfection, cell viability and cell prolifera-
tion was 94.4% in ESM-1-siRNA transfected PC-3 cells 
compared to PC-3 cells transfected with control-siRNA. 
Thus, ESM-1 siRNA knockdown did not significantly af-
fect cell proliferation of PC-3 cells. 
Effect of ESM-1 siRNA knockdown in migration of 
PC-3 cells 
A wound healing assay revealed that 48 h after scratch 
treatment, the open wound area of ESM-1 siRNA-trans-
fected cells was significantly larger compared to that of 
control-siRNA-transfected or untransfected cells (Figure 
4). Thus, knockdown of ESM-1 in PC-3 cells inhibited cell 
migration in vitro. 
DISCUSSION
Prostate cancer is the most frequently diagnosed non-
skin cancer in the United States (24) and the incidence of 
metastatic prostate cancer has increased in the last de-
cade in this country (25). Increasing efforts have been ad-
dressed to understand the biology of this disease. Endocan 
is a soluble proteoglycan that is overexpressed by meta-
static cell lines from different origins, including prostate 
(3, 4), glioblastoma (7), colon cancer (26), among others. 
It has been also found circulating in the bloodstream of 
healthy individuals, patients with inflammatory diseases 
and cancer patients (9, 11, 27). Increasing evidence shows 
the involvement of this proteoglycan in the control of 
fundamental cellular processes such as adhesion, migra-
tion and angiogenesis (28). Among these, angiogenesis is 
central for cancer progression, and it is regulated by both 
activator and inhibitor molecules, including endocan and 
CXC chemokines, which are increasingly shown to play a 
key role in angiogenesis of cancer (28, 29). So far, the role 
of endocan in prostate cancer remains unknown. 
In the present study we investigated whether siRNA-
mediated silencing of endocan expression affected prolif-
eration, migration and/or CXC chemokine expression of 
PC-3 cells. We found that siRNA-mediated silencing of 
endocan expression in the highly metastatic prostate can-
cer cell line PC-3 results in decreased migration with no 
Figure 3. Cell viability and proliferation of siRNA transfected 
PC-3 cells. Cell survival (A) and proliferation rate (B) of PC-3 
cells transfected with siESM-1 or siControl, were analyzed 48 
h post-transfection using a MTS-based colorimetric test and 
direct cell counting trypan blue dye exclusion, respectively. 
Knockdown of ESM-1 did not affect cell viability or prolifera-
tion of PC-3 cells. siControl: PC-3 cells transfected with control 
siRNA. siESM-1: PC-3 cells transfected with ESM-1 siRNA.
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effect on cell proliferation. Consistent with previous re-
sults in other cell types (30, 31), endocan silencing in PC-3 
cells resulted in decreased cell migration in in vitro assays. 
Since endocan is regarded as a marker of angiogenesis, a 
process that has been shown to be regulated by several 
factors, including the CXC chemokine family (15), we fur-
ther examined whether endocan knockdown in these cells 
affected the mRNA expression of CXC chemokines. We 
found that endocan gene-silencing in PC-3 cells was ac-
companied by decreased expression of CXCL3, a member 
of the angiogenic ELR+ CXC chemokine group. 
CXCL3 and its receptor CXCR2 have been recently 
found overexpressed in prostate cancer cells, prostate epi-
thelial cells and prostate cancer tissues, which may impli-
cate a role for this chemokine in prostate cancer progres-
sion and metastasis (32). CXCL3 is a member of the CXC 
chemokine family and it is sub-classified as a Glu-Leu-
Arg (ELR+) CXC chemokine (33). CXCL3 has been found 
previously over-expressed in the aggressive PC-3 cell line 
and its tissue expression correlates with prostate cancer 
metastasis (32, 34). Our results show that ESM-1 target-
ing in PC-3 cells resulted in decreased migration, which 
may be related, at least in part, to decreased expression of 
the angiogenic CXCL3 chemokine whose expression was 
found to be reduced in endocan siRNA transfected cells. 
CXCL3 has been shown to act as a chemoattractant for 
neutrophils to areas of brain injury (35) and for cerebel-
lar progenitor cells (36), while it is not clear for prostate 
cancer cells if this chemokine is chemoattractant or not 
(32). The results shown here deserve further investigation. 
Additional studies are required to determine the mecha-
nisms underlying the decreased expression of CXCL3 in 
endocan siRNA silenced PC-3 cells, and more research is 
needed to ascertain the biological role of ESM-1 in pros-
tate cancer. It will be important to determine the effects of 
ESM-1 knockdown in other recognized angiogenic mark-
ers and the effects of ectopically expressing ESM-1 in cells 
with ESM-1 knockdown. 
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